Voices

``Our strategy (international expansion) has been to leverage and complement the considerable in-house strengths of brand marketing, generic product pipeline, cost-effective technologies and strong backward integration. Our international operations already make up a significant part of our corporate revenues. We expect them hereafter, to contribute increasingly to the company's growth and profit objectives.'' -- Mr D. S. Brar, CEO and Managing Director, Ranbaxy Laboratories

``The challenge for Cipla is to maintain its momentum amidst all these uncertainties. The company is confident that it will continue to capitalise on emerging business opportunities, given its technological strengths and strong presence across a wide range of therapeutic segments.'' -- Directors' Report 2000-01, Cipla

``Our achievements in drug discovery are testimony to our belief that there is little correlation between innovation and size.'' -- Dr Anji Reddy, Chairman, Dr Reddy's Labs

``Instead they and others in the pharmaceutical industry are now suggesting by innuendo to the FDA that certain concerns may exist with regard to generic products but not to their own. Andrx is firm in its belief that these latest moves are merely transparent ploys to prevent or delay the entry of generics.'' -- Mr Elliot Hahn, President, Andrx Corp, reacting to developments in the legal battle with the Prilosec patent holder, AstraZeneca

``The contribution from generics is expected to improve substantially. The focus in this business will be on being the most cost-competitive provider of finished dosages to pharmaceutical companies in regulated markets. The strategy will be to expedite the product launches and use multiple alliance relationships in different markets to optimise returns and manage risks.'' -- Dr Anji Reddy, Chairman, Dr Reddy's Labs

``The actual value creation from genomics is likely to be only in the distant future. At the moment, it is putting increasing cost pressure on drug discovery research because of large investments required upfront.'' -- Mr Ajay Piramal, Chairman, Nicholas Piramal India